We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Diagnostic value of <sup>18</sup>F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8<sup>+</sup>tumour-infiltrating lymphocytes in oral squamous cell carcinoma.
- Authors
Togo, Maria; Yokobori, Takehiko; Shimizu, Kimihiro; Handa, Tadashi; Kaira, Kyoichi; Sano, Takaaki; Tsukagoshi, Mariko; Higuchi, Tetsuya; Yokoo, Satoshi; Shirabe, Ken; Oyama, Tetsunari
- Abstract
<bold>Background: </bold>Lately, immune checkpoint proteins, such as programmed death 1 (PD-1) and its ligand-1 (PD-L1), have garnered attention as a new target in oral squamous cell carcinoma (OSCC). Reportedly, fluoro-D-glucose (FDG)-uptake alteration by anti-PD-1 antibody treatment depicts the response in patients with lung cancer. This study aims to elucidate the correlations between tumour immune status, clinicopathological factors, 18F-FDG-uptake and cold tumour phenotypes as low PD-L1 expression/low CD8+tumour-infiltrating lymphocytes (TILs) in OSCC.<bold>Methods: </bold>We performed immunohistochemical analysis of PD-L1, hypoxia-inducible factor 1 A (HIF-1A), glucose transporter type 1 (GLUT1), CD8, E-cadherin and Ki-67 on 59 operable OSCC samples. We assessed the correlations between these factors and preoperative 18F-FDG-uptake, clinicopathological characteristics and prognosis.<bold>Results: </bold>Low expression of PD-L1 in OSCC correlated with cancer aggressiveness, poor prognosis, high 18F-FDG-uptake with HIF-1A/GLUT1 and low E-cadherin expression and low CD8. Cold tumour phenotypes as low PD-L1 tumour cells and low stromal CD8 correlated with the poor prognosis, high 18F-FDG-uptake and E-cadherin suppression. Furthermore, the high level of preoperative 18F-FDG-uptake in OSCC was an independent predictor of the cold tumour immune status.<bold>Conclusions: </bold>18F-FDG-uptake is an independent predictor of cold tumour in OSCC. 18F-FDG-PET imaging could be a promising diagnostic tool to estimate tumour immune status.
- Publication
British Journal of Cancer, 2020, Vol 122, Issue 11, p1686
- ISSN
0007-0920
- Publication type
journal article
- DOI
10.1038/s41416-020-0820-z